Amber Bio co-founders Jacob Borrajo (L) and Basem Al-Shayeb

Play­ground Glob­al, a16z back $26M seed for RNA edit­ing start­up aim­ing to ad­dress mul­ti­ple mu­ta­tions with sin­gle shot

The ad­vent of CRISPR tech­nolo­gies for gene edit­ing has opened up the pos­si­bil­i­ty of treat­ing ge­net­ic dis­or­ders by mak­ing pre­cise changes to pa­tients’ DNA or RNA. But two young sci­en­tists be­lieve that for the field to have a big­ger im­pact, it needs to go broad­er.

Basem Al-Shayeb and Ja­cob Bor­ra­jo are co-founders of Am­ber Bio, which is tak­ing the wraps off a $26 mil­lion seed round to test a new RNA edit­ing plat­form that they hope can make “mul­ti-kilo­base ed­its” — es­sen­tial­ly re­plac­ing whole sec­tions of RNA when need­ed. The round was co-led by Play­ground Glob­al and An­dreessen Horowitz Bio + Health, with par­tic­i­pa­tion from Eli Lil­ly, RDF (Reti­nal De­gen­er­a­tion Fund), Hum­ming­bird Ven­tures and Pil­lar VC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.